Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Want to cut your energy bills? Here’s how five experts are doing it 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
MALVERN, Pa., Feb. 23, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its fourth quarter financial results before the market opens on March 15, 2017
Management will conduct a conference call at 8:00 a.m. ET that day to discuss the Company’s financial results and provide a general business update. The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Company’s website for 30 days following the call.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 62366728 prior to the start of the call.
About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
